Abstracts tagged "histone acetylation"

Abstract Number: 1660 • 2017 ACR/ARHP Annual Meeting
Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song³ and Kathleen E. Sullivan⁴, ¹Temple University, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Epigenetic changes in systemic lupus erythematosus (SLE) offer a potential explanation for the chronicity of disease. We previously found that interferon regulatory factor-1(IRF1) binding…
Abstract Number: 1628 • 2015 ACR/ARHP Annual Meeting
A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis
Yu Jin Jang¹, Bo Ram Oh², Hyojin Lim³, Daekwon Bae³, Nina Ha³, Young il Choi⁴, Jin Kyun Park⁵, Eun Young Lee⁵, Eun Bong Lee⁵ and Yeong Wook Song^5,6, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea, ³Department of Pharmacology and Toxicology, CKD Research Institute, CKD Pharmaceutical Company, Seoul, South Korea, ⁴315-20 dongbaekjukjeon-daero, giheung-gu, Pharmacology lab, Hyo-Jong Research Laboratories, CKD Pharmaceutical Company, Yongin-si, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea
Background/Purpose: Epigenetic changes including histone modification play an important role in development of rheumatoid arthritis (RA). Histone deacetylase inhibitor (HDACi) increases transcription of numerous genes…
Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Eun Chung Hong¹, Hemin Jeong², Jiwon Hwang², Eun-Kyung Bae¹, Hyungjin Kim², Joong Kyong Ahn³, Hoon-Suk Cha², Eun-mi Koh⁴ and Jaejoon Lee⁴, ¹Samsung Biomedical Research Institute, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Sungkyunkwan univ. school of medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].